1. Home
  2. STTK vs INTT Comparison

STTK vs INTT Comparison

Compare STTK & INTT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STTK
  • INTT
  • Stock Information
  • Founded
  • STTK 2016
  • INTT 1981
  • Country
  • STTK United States
  • INTT United States
  • Employees
  • STTK N/A
  • INTT N/A
  • Industry
  • STTK Biotechnology: Pharmaceutical Preparations
  • INTT Semiconductors
  • Sector
  • STTK Health Care
  • INTT Technology
  • Exchange
  • STTK Nasdaq
  • INTT Nasdaq
  • Market Cap
  • STTK 83.8M
  • INTT 89.8M
  • IPO Year
  • STTK 2020
  • INTT 1997
  • Fundamental
  • Price
  • STTK $1.92
  • INTT $7.25
  • Analyst Decision
  • STTK Hold
  • INTT Strong Buy
  • Analyst Count
  • STTK 6
  • INTT 2
  • Target Price
  • STTK $2.67
  • INTT $12.00
  • AVG Volume (30 Days)
  • STTK 1.6M
  • INTT 50.3K
  • Earning Date
  • STTK 08-14-2025
  • INTT 10-31-2025
  • Dividend Yield
  • STTK N/A
  • INTT N/A
  • EPS Growth
  • STTK N/A
  • INTT N/A
  • EPS
  • STTK N/A
  • INTT N/A
  • Revenue
  • STTK $2,997,000.00
  • INTT $121,642,000.00
  • Revenue This Year
  • STTK N/A
  • INTT N/A
  • Revenue Next Year
  • STTK N/A
  • INTT $10.38
  • P/E Ratio
  • STTK N/A
  • INTT N/A
  • Revenue Growth
  • STTK N/A
  • INTT N/A
  • 52 Week Low
  • STTK $0.69
  • INTT $5.24
  • 52 Week High
  • STTK $3.95
  • INTT $9.77
  • Technical
  • Relative Strength Index (RSI)
  • STTK 72.13
  • INTT 53.40
  • Support Level
  • STTK $1.68
  • INTT $7.08
  • Resistance Level
  • STTK $2.04
  • INTT $7.31
  • Average True Range (ATR)
  • STTK 0.19
  • INTT 0.29
  • MACD
  • STTK 0.09
  • INTT 0.02
  • Stochastic Oscillator
  • STTK 89.29
  • INTT 50.66

About STTK Shattuck Labs Inc.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

About INTT inTest Corporation

inTest Corp is a supplier of test and process solutions for use in manufacturing and testing across a range of markets including automotive, defense/aerospace, industrial, medical, semiconductor and telecommunications. The company manages its business as three operating segments which is also their reporting units that includes Electronic Test, Environmental Technologies and Process Technologies. Electronic Test (which includes semiconductor test equipment, flying probe and in-circuit testers), Environmental Technologies (which includes its thermal test, process and storage products) and Process Technologies (which includes induction heating and video imaging products). The company operates their business and sells its products both domestically and internationally.

Share on Social Networks: